A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

The aim of this study is to define the maximum tolerated dose (MTD), safety, pharmacokinetics (PKs) and efficacy of ispinesib (SB-715992) in combination with docetaxel. Patients with advanced solid tumours were treated with ispinesib (6–12 mg m(−2)) and docetaxel (50–75 mg m(−2)). Docetaxel was admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Blagden, S P, Molife, L R, Seebaran, A, Payne, M, Reid, A H M, Protheroe, A S, Vasist, L S, Williams, D D, Bowen, C, Kathman, S J, Hodge, J P, Dar, M M, de Bono, J S, Middleton, M R
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266864/
https://www.ncbi.nlm.nih.gov/pubmed/18319713
http://dx.doi.org/10.1038/sj.bjc.6604264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2266864/
https://www.ncbi.nlm.nih.gov/pubmed/18319713
http://dx.doi.org/10.1038/sj.bjc.6604264

Ejemplares similares